Rigel Pharmaceuticals | RIGL - Cost Of Sales


Rigel Pharmaceuticals reported $8.03M in Cost of Sales for its fiscal quarter ending in September of 2024.





Cost Of Sales Change Date
Agenus USD 642K 399K Sep/2025
Amgen USD 1.87B 271M Jun/2026
Anika Therapeutics USD 11.44M 797K Dec/2025
AstraZeneca USD 2.52B 2.73B Jun/2026
BioMarin Pharmaceutical USD 276.29M 76.8M Jun/2026
Bristol-Myers Squibb USD 7.89B 4.03B Jun/2026
Celldex Therapeutics USD 54.2M 8.94M Jun/2025
Daiichi Sankyo JPY 124.29B 6.02B Jun/2026
Eli Lilly USD 3.27B 309M Jun/2026
Halozyme Therapeutics USD 108.68M 67K Jun/2026
Heron Therapeutics USD 11.12M 795K Dec/2025
Intrexon USD 1.01M 344K Jun/2024
Ionis Pharmaceuticals USD 2.74M 261K Jun/2026
Karyopharm Therapeutics USD 1.34M 139K Mar/2026
Ligand Pharmaceuticals USD 11.31M 59K Jun/2026
MacroGenics USD 9.53M 585K Mar/2026
Neurocrine Biosciences USD 39.4M 25.6M Jun/2026
Pfizer USD 4.09B 498M Jun/2026
Regeneron Pharmaceuticals USD 576.5M 92.9M Jun/2026
Rigel Pharmaceuticals USD 8.03M 5.22M Sep/2024
Sangamo BioSciences 2.42M 1.11M Jun/2024
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
Veracyte USD 42.19M 3.7M Jun/2026